| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
EML 425 (EML425, Compound 7h) is a strong, reversible, and specific inhibitor of CBP/p300. It exhibits good cell permeability and is non-competitive with acetyl-CoA and histone H3 peptides. EML 425 exhibits minimal activity against the general control non-derepressor 5 (GCN5) and p300/CBP-associated factor (PCAF) enzymes, but it effectively suppresses p300 and CBP (IC50 values 2.9 and 1.1 μM, respectively). EML 425 substantially and time-dependently acetylates lysine H4K5 and H3K9 in U937 cells. It was demonstrated that EML 425 is a reversible inhibitor with uneven affinity constants that can bind both free enzyme and enzyme-substrate complexes. It is also non-competitive with acetyl-CoA and histone H3 peptides. According to the best-scoring docking position, the binding site for EML 425 is an alternate pocket that is situated close to the acetylation site and close to the substrate's lysine binding groove [1].
|
|---|---|
| References |
| Molecular Formula |
C27H24N2O4
|
|---|---|
| Molecular Weight |
440.5
|
| Exact Mass |
440.173
|
| CAS # |
1675821-32-5
|
| PubChem CID |
91826273
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
622.8±65.0 °C at 760 mmHg
|
| Flash Point |
330.5±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.683
|
| LogP |
4.71
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
710
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LUGQBJDYUPNAQQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H24N2O4/c1-18-13-22(30)14-19(2)23(18)15-24-25(31)28(16-20-9-5-3-6-10-20)27(33)29(26(24)32)17-21-11-7-4-8-12-21/h3-15,30H,16-17H2,1-2H3
|
| Chemical Name |
1,3-dibenzyl-5-[(4-hydroxy-2,6-dimethylphenyl)methylidene]-1,3-diazinane-2,4,6-trione
|
| Synonyms |
EML425; EML-425; EML 425
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~567.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2701 mL | 11.3507 mL | 22.7015 mL | |
| 5 mM | 0.4540 mL | 2.2701 mL | 4.5403 mL | |
| 10 mM | 0.2270 mL | 1.1351 mL | 2.2701 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
